Sumiyoshi Kiguchi

No ORCID on file · 4 papers in corpus · active 2022-2023

Study types

  • other 3
  • article 1

Condition tags

  • endometriosis 3
other 2023
Suppression of hypothalamic-pituitary-gonadal function by linzagolix in benign prostatic hyperplasia and polycystic ovary syndrome animal models
Clinical and experimental pharmacology & physiology ·doi:10.1111/1440-1681.13817

The hypothalamic-pituitary-gonadal (HPG) axis is an important regulatory mechanism involved primarily in the development and regulation of the reproductive systems. The suppression of the HPG axis by gonadotropin-releasing hormone (GnRH) an…

other 2023
Suppressive effects of linzagolix, a novel non-peptide antagonist of gonadotropin-releasing hormone receptors, in experimental endometriosis model rats
Clinical and experimental pharmacology & physiology ·doi:10.1111/1440-1681.13778

Endometriosis is an oestrogen-dependent disease in which endometrial-like tissue grows outside the uterus in women of reproductive age. Accordingly, control of oestradiol (E2) levels is an effective treatment for endometriosis. Because gona…

article 2022
Non-clinical studies indicating lack of interactions between iron/calcium ions and linzagolix, an orally available GnRH antagonist
·doi:10.1080/00498254.2022.2109076

Linzagolix is an orally available gonadotropin-releasing hormone antagonist used to treat sex-hormone-dependent diseases in women. This study aimed to investigate drug-drug interactions between linzagolix and iron/calcium ions in the intend…

other 2022
Pharmacological characterization of linzagolix, a novel, orally active, non-peptide antagonist of gonadotropin-releasing hormone receptors
Clinical and experimental pharmacology & physiology ·doi:10.1111/1440-1681.13688

Control of gonadotropin-releasing hormone (GnRH) signalling is an effective strategy for the treatment of sex hormone-dependent diseases. GnRH analogues have been widely used for treating these diseases; however, initial stimulation or comp…